Aurinia Pharmaceuticals Inc:Leerink Partners将评级从“跑赢大盘”下调至“市场表现”,同时将目标价上调至16美元,之前为15美元。
Aurinia Pharmaceuticals Inc:Leerink Partners将评级从“跑赢大盘”下调至“市场表现”,同时将目标价上调至16美元,之前为15美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.